Pharma Stocks Fall After Trump Pressures Companies to Cut Drug Costs

President Trump has sent letters to 17 major pharmaceutical companies, urging them to reduce US prescription drug prices to match those in other developed countries.

The Details: Letters were sent to chief executives of companies including Eli Lilly, Sanofi, Regeneron, Merck & Co, Johnson & Johnson, and AstraZeneca, asking them to provide most-favored-nation prices to every Medicaid patient, and a guarantee of such pricing for new drugs. He also called on companies to bring back excess revenue generated from higher prices overseas to help offset lower prices in the US. Trump threatened to use every tool at his disposal to protect Americans from high drug pricing if the companies refused to comply. He set a deadline of September 29 to respond with binding commitments to these terms.

For Context: US patients pay nearly three times more for prescription medicines than those in other developed nations. Trump signed an executive order in May requiring drugmakers to cut US medicine prices to match those abroad. Pharmaceutical companies argue that high prescription costs fund US investment in pharmaceutical research and development, and that drastic price cuts would stifle innovation.

How the Media Covered It: Bloomberg (Lean Left bias) included the pharmaceutical industry’s opposition, citing concerns about innovation and global competitiveness. It noted that while some companies pledged cooperation, PhRMA pushed back, warning China could benefit. The Wall Street Journal (Center) highlighted the financial fallout from Trump’s demand, noting a sharp drop in global pharmaceutical stocks for companies like Novo Nordisk, AstraZeneca, and GSK. Fox Business (Lean Right) framed the action as part of Trump’s broader effort to lower prescription prices and help American families.

Revised by the AllSides staff (of humans) after a first draft from our custom AI. Learn more. Support our mission. Suggest an improvement to this summary.